research use only

SHR2554 EZH2 inhibitor

Name: SHR2554
Brand: Selleck Chemicals
SKU: E1521
Availability: InStock
Rating: 5 (1 reviews)

Cat.No.E1521

SHR2554 is an inhibitor of EZH2. SHR2554 exhibits anti-tumor activity with IC50 values ranging from 0.365 to 3.001 μM in a dose-dependent manner, in T-cell lymphoma (TCL) by reducing H3K27me3 levels.

Chemical Structure

Molecular Weight: 548.72

Jump to

Quality Control

Batch: Purity: 99.38%

99.38

Related Targets	PRMT MAT2A DNA Methyltransferase LSD1 JMJD G9a/GLP MLL NSD FTO SETD
Other EZH2 Inhibitors	PF-06821497 GSK126 Tulmimetostat (CPI-0209) Valemetostat (DS-3201) GSK343 Lirametostat (CPI-1205) CPI-169 MS1943 EZH2/HSP90-IN-29 EBI-2511

Solubility

In vitro
Batch:

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	5mg/ml (9.11mM)	Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	548.72	Formula	C₃₂H₄₄N₄O₄	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	2098545-98-1	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent

Read more about storage stability stock solution CAS number

Mechanism of Action

References	[1] https://pubmed.ncbi.nlm.nih.gov/40659662/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-05-01)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07562568	NOT_YET_RECRUITING	Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; MDS; Transplantation, Stem Cell; Conditioning Therapy; SHR2554; Azacytidine	The First Affiliated Hospital of Soochow University	2026-06	PHASE2
NCT07615283	NOT_YET_RECRUITING	Relapsed or Refractory Peripheral T Cell Lymphoma; NKTCL	Sun Yat-sen University	2026-05-29	PHASE1; PHASE2
NCT07575412	NOT_YET_RECRUITING	Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; MDS; Transplantation, Stem Cell; Conditioning Therapy; SHR2554; Azacytidine	The First Affiliated Hospital of Soochow University	2026-06	PHASE2
NCT07347288	NOT_YET_RECRUITING	PTCL	The First Affiliated Hospital with Nanjing Medical University	2026-02	PHASE2
NCT07230106	RECRUITING	Prostate Cancer	Jiangsu HengRui Medicine Co., Ltd.	2025-12-08	PHASE2
NCT07175220	RECRUITING	Locally Advanced or Metastatic Non-small Cell Lung Cancer	Jiangsu HengRui Medicine Co., Ltd.	2025-10-09	PHASE2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):